Citations (17)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Hirohito Shimizu, Hisanori Kobayashi, Masayoshi Kanbori & Yutaka Ishii. (2021) Effectiveness of golimumab in rheumatoid arthritis patients with inadequate response to first-line biologic therapy: Results from a Japanese post-marketing surveillance study. Modern Rheumatology 31:3, pages 556-565.
Read now
Read now
Katsuhiko Takabayashi, Fumihiko Ando & Takahiro Suzuki. (2019) Comparing the effectiveness of biological disease-modifying antirheumatic drugs using real-world data. Modern Rheumatology 29:1, pages 87-97.
Read now
Read now
Benjamin Chastek, Laura K. Becker, Chieh-I Chen, Puneet Mahajan & Jeffrey R. Curtis. (2017) Outcomes of tumor necrosis factor inhibitor cycling versus switching to a disease-modifying anti-rheumatic drug with a new mechanism of action among patients with rheumatoid arthritis. Journal of Medical Economics 20:5, pages 464-473.
Read now
Read now
Articles from other publishers (14)
Gerasimos Evangelatos, Giorgos Bamias, George D. Kitas, George Kollias & Petros P. Sfikakis. (2022) The second decade of anti-TNF-a therapy in clinical practice: new lessons and future directions in the COVID-19 era. Rheumatology International 42:9, pages 1493-1511.
Crossref
Crossref
Marco Sebastiani, Vincenzo Venerito, Serena Bugatti, Chiara Bazzani, Martina Biggioggero, Luca Petricca, Rosario Foti, Alessandra Bortoluzzi, Silvia Balduzzi, Elisa Visalli, Bruno Frediani, Andreina Manfredi, Elisa Gremese, Ennio Favalli, Florenzo Iannone, Gianfranco Ferraccioli, Giovanni Lapadula, Elena Galli, Francesco Paolo Cantatore, Claudia Lomater, Fabiola Atzeni, Roberto Gorla, Enrico Fusaro, Fausto Salaffi, Fabrizio Conti, Alberto Cauli, Piercarlo Sarzi-Puttini, Antonio Carletto & Giuseppe Lopalco. (2021) Retention rate of a second line with a biologic DMARD after failure of a first-line therapy with abatacept, tocilizumab, or rituximab: results from the Italian GISEA registry. Clinical Rheumatology 40:10, pages 4039-4047.
Crossref
Crossref
Ko-Jen Li, Chia-Li Chang, Chih-Yi Hsin & Chao-Hsiun Tang. (2021) Switching and Discontinuation Pattern of Biologic Disease-Modifying Antirheumatic Drugs and Tofacitinib for Patients With Rheumatoid Arthritis in Taiwan. Frontiers in Pharmacology 12.
Crossref
Crossref
Pascal Hilliquin, Thomas Barnetche, Athan Baillet, René-Marc Flipo, Eric Lespessailles, Christian Roux, Patrice Fardellone, Anika Gilbert-Marceau, Isabelle Idier, Arnaud Constantin, Emilie Shipley, Guy Baudens & Alain Saraux. (2020) Real-World 1-Year Retention Rate of Subcutaneous Tocilizumab Treatment in Patients with Moderate to Severe Active Rheumatoid Arthritis: TANDEM Study. Rheumatology and Therapy 8:1, pages 95-108.
Crossref
Crossref
Takayasu Ando, Takeshi Suzuki, Yutaka Gotou, Mitsuru Imamura, Hiroko Nagafuchi, Yoshioki Yamasaki, Seido Ooka & Kimito Kawahata. (2019) Early Response of DAS28-ESR (3) Predicts Sustained Response to Tocilizumab Switched from Abatacept. Journal of St. Marianna University 10:2, pages 39-49.
Crossref
Crossref
Monica Todoerti, Ennio Giulio Favalli, Florenzo Iannone, Ignazio Olivieri, Maurizio Benucci, Alberto Cauli, Alessandro Mathieu, Leonardo Santo, Giovanni Minisola, Giovanni Lapadula, Romano Bucci, Elisa Gremese & Roberto Caporali. (2018) Switch or swap strategy in rheumatoid arthritis patients failing TNF inhibitors? Results of a modified Italian Expert Consensus. Rheumatology 57:Supplement_7, pages vii42-vii53.
Crossref
Crossref
Patrick Durez. (2018) Switching of biologics in RA patients who do not respond to the first biologic. Joint Bone Spine 85:4, pages 395-397.
Crossref
Crossref
Min-Young Lee, Ju-Young Shin, Sun-Young Park, Donguk Kim, Hoon-Suk Cha & Eui-Kyung Lee. (2018) Persistence of biologic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: An analysis of the South Korean National Health Insurance Database. Seminars in Arthritis and Rheumatism 47:4, pages 485-491.
Crossref
Crossref
Patrick Durez. (2018) Rotation des biothérapies en cas de réponse inadéquate à un premier agent biologique dans la polyarthrite rhumatoïde. Revue du Rhumatisme Monographies 85:1, pages 15-18.
Crossref
Crossref
Fabrizio Cantini, Laura Niccoli, Carlotta Nannini, Emanuele Cassarà, Olga Kaloudi, Ennio Giulio Favalli, Andrea Becciolini, Maurizio Benucci, Francesca Li Gobbi, Serena Guiducci, Rosario Foti, Marta Mosca & Delia Goletti. (2017) Second-line biologic therapy optimization in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. Seminars in Arthritis and Rheumatism 47:2, pages 183-192.
Crossref
Crossref
Wenhui Wei, Keith Knapp, Li Wang, Chieh-I Chen, Gary L. Craig, Karen Ferguson & Sergio Schwartzman. (2017) Treatment Persistence and Clinical Outcomes of Tumor Necrosis Factor Inhibitor Cycling or Switching to a New Mechanism of Action Therapy: Real-world Observational Study of Rheumatoid Arthritis Patients in the United States with Prior Tumor Necrosis Factor Inhibitor Therapy. Advances in Therapy 34:8, pages 1936-1952.
Crossref
Crossref
Ennio Giulio Favalli, Francesca Pregnolato, Martina Biggioggero, Andrea Becciolini, Alessandra Emiliana Penatti, Antonio Marchesoni & Pier Luigi Meroni. (2016) Twelve-Year Retention Rate of First-Line Tumor Necrosis Factor Inhibitors in Rheumatoid Arthritis: Real-Life Data From a Local Registry. Arthritis Care & Research 68:4, pages 432-439.
Crossref
Crossref
A. Rubbert-Roth. (2015) Wechsel innerhalb der Wirkstoffgruppe oder Wechsel des WirkprinzipsSwitching within the active ingredient group or changing the mechanism of action. rheuma plus 14:4, pages 100-108.
Crossref
Crossref
A. Rubbert-Roth. (2015) Wechsel innerhalb der Wirkstoffgruppe oder Wechsel des WirkprinzipsSwitching within the active ingredient group or changing the mechanism of action. Zeitschrift für Rheumatologie 74:5, pages 406-413.
Crossref
Crossref